Ozempic Online: How Telehealth Prescribing Works

Does 'Ozempic online' mean Ozempic, or compounded semaglutide?

Two different products can be involved under that phrase.

Ozempic is Novo Nordisk's FDA-approved semaglutide injection, first approved on 2017-12-05 under NDA 209637 [6]. Semaglutide tablets are also marketed as Ozempic, at 1.5, 4 and 9 mg, under the Rybelsus approval (NDA 213051, first approved 2019-09-20) [7]. Wegovy is a separate semaglutide product: an injection approved 2021-06-04, and tablets approved 2025-12-22 [4][8], with its own weight-management indication [10].

The Ozempic injection label covers three uses, all in type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with chronic kidney disease [2]. The Ozempic tablets label covers glycemic control in adults with type 2 diabetes and reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events [3]. Neither label is a weight-loss label. The Ozempic injection label says safety and efficacy have not been established in pediatric patients [2].

An online offer for a weekly semaglutide injection may be for Ozempic or for a compounded semaglutide product. FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [1].

What an online prescription actually requires

FDA's consumer guidance on unapproved GLP-1 drugs lists the warning signs it wants patients to look for. A company is a red flag if it does not require a screening and prescription by a licensed doctor before providing medicine, or if it does not have a licensed doctor available to answer questions after you receive the medication [1]. Other listed red flags: claiming the compounded drug is the same as an FDA-approved drug, sending medicine that looks different from what was pictured or arrives in broken or damaged packaging or without instructions for use, spelling errors on the label or incorrect pharmacy addresses, and a pharmacy name on the label that might be fraudulent [1].

FDA also recommends that patients obtain a prescription from a doctor and fill it at a state-licensed pharmacy [1].

How FDA limits compounded semaglutide

A pharmacy may compound only for an individual patient on a prescription, and a product that is essentially a copy of an approved drug is allowed only if made rarely — FDA says it does not intend to act against four or fewer such prescriptions per calendar month — or if the prescriber documents a significant difference for that patient [5].

FDA says a product that adds another ingredient such as vitamin B12 to semaglutide may still be essentially a copy if the route is the same and each strength is within 10% of the commercial product [5]. Outsourcing facilities generally cannot compound from bulk substances unless the substance is on FDA's bulks list for outsourcing facilities, and FDA says semaglutide is not on that list [5].

On 2026-04-30 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from that list, finding no clinical need for outsourcing facilities to compound them from bulk substances. Comments were due 2026-06-29 and FDA says no final decision has been made [9].

What FDA has flagged in compounded semaglutide

FDA's safety concerns are specific. As of 2026-05-31 the agency had received 990 adverse event reports for compounded semaglutide and says this likely undercounts the real number [1]. It reports dosing errors with compounded injectable semaglutide: patients measuring the wrong dose, clinicians miscalculating, and doses above the label [1]. FDA also says semaglutide sodium and semaglutide acetate salts are different active ingredients from the approved drug, with no lawful basis for use in compounding that the agency is aware of, and it warns about counterfeit Ozempic [1].

Handling matters too. FDA recommends that multi-dose vials of sterile medication be discarded within 28 days of first use, even if medicine remains, and not used longer even if the compounder's instructions say otherwise, with a new sterile needle and syringe for every dose [1]. Injectable GLP-1 drugs require refrigeration, and FDA recommends not using an injectable GLP-1 that arrives warm or with inadequate ice packs [1].

What the prescription itself looks like

For Ozempic injection, the label starts adults at 0.25 mg once weekly for 4 weeks — a dose that is not a maintenance dose — then 0.5 mg once weekly. If more glycemic control is needed, the dose goes to 1 mg after at least 4 weeks on 0.5 mg, then to 2 mg after at least 4 weeks on 1 mg, with a maximum of 2 mg weekly. For the kidney indication, the label increases to 1 mg after at least 4 weeks on 0.5 mg. The label says to give a missed dose within 5 days, otherwise skip it [2].

The Ozempic injection label carries a boxed warning about thyroid C-cell tumors [2]. Ozempic tablets carry the warning too [3]. In rodents, semaglutide caused dose- and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; whether it causes such tumors, including medullary thyroid carcinoma, in humans is unknown. Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2].

The Ozempic injection label also covers acute pancreatitis (the label says to discontinue Ozempic if it is suspected), gallbladder disease, hypoglycemia when used with insulin or a sulfonylurea, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy monitoring, pulmonary aspiration during general anesthesia or deep sedation, and a warning never to share a pen between patients [2]. The label states the drug is not recommended in patients with severe gastroparesis [2].